ConductScience.org, home

Paper41501059

Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases.

Kong F and 8 others. Nat Commun, 2026. Cited by 22 papers, by iCite.

Cite this record

ConductScience Library. Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases. Papers, record 41501059. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41501059

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Comprehensive evaluation of GLP-1 receptor agonists: an umbrella review of clinical outcomes across multiple diseases.
PubMed
Journal
Nat Commun
PubMed
Year
2026
PubMed
Publication types
Journal Article, Systematic Review
PubMed
Citations, by iCite
22
iCite
Relative citation ratio, by iCite
13.93, provisional
iCite
Revised in PubMed
2026-01-31
PubMed

Authors9

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Kong FFanjinghttps://orcid.org/0009-0004-1453-8562
2Zhao YYanru
3Zhang WWeiming
4Wang XXinyi
5Wu TTianyuhttps://orcid.org/0009-0003-0206-3101
6Zhou ZZiyi
7Xu YYinghttps://orcid.org/0000-0003-1445-4997
8Xia LLinahttps://orcid.org/0000-0001-5338-9126
9Sun TTaohttps://orcid.org/0000-0003-2773-9174

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Glucagon-Like Peptide-1 Receptor AgonistsMajor topic
Diabetes Mellitus, Type 2Major topic
Hypoglycemic AgentsMajor topic
Humans
Treatment Outcome
Meta-Analysis as Topic
Glucagon-Like Peptide-1 Receptor

Source PubMed

Download CSV of topics

References60

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
136396031Glucagon-like Peptide-1 receptor Tie2+ cells are essential for the cardioprotective actions of liraglutide in mice with experimental myocardial infarction.Mol Metab2022https://conductscience.org/library/papers/36396031PubMed
236620987Mechanisms and possible hepatoprotective effects of glucagon-like peptide-1 receptor agonists and other incretin receptor agonists in non-alcoholic fatty liver disease.Lancet Gastroenterol Hepatol2023https://conductscience.org/library/papers/36620987PubMed
317928588The physiology of glucagon-like peptide 1.Physiol Rev2007https://conductscience.org/library/papers/17928588PubMed
438542021Novel Antidiabetic Drugs and the Risk of Diabetic Retinopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.J Clin Med2024https://conductscience.org/library/papers/38542021PubMed
528538729Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein.Nature2017https://conductscience.org/library/papers/28538729PubMed
637796527Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss.JAMA2023https://conductscience.org/library/papers/37796527PubMed
731195981miR-122 promotes hepatic lipogenesis via inhibiting the LKB1/AMPK pathway by targeting Sirt1 in non-alcoholic fatty liver disease.Mol Med2019https://conductscience.org/library/papers/31195981PubMed
821195583GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables.J Clin Epidemiol2011https://conductscience.org/library/papers/21195583PubMed
939089293Efficacy and safety of once-weekly semaglutide 2·4 mg versus placebo in people with obesity and prediabetes (STEP 10): a randomised, double-blind, placebo-controlled, multicentre phase 3 trial.Lancet Diabetes Endocrinol2024https://conductscience.org/library/papers/39089293PubMed
1030728472Antibodies and venom peptides: new modalities for ion channels.Nat Rev Drug Discov2019https://conductscience.org/library/papers/30728472PubMed
1138031234Incretin-based drugs and the risk of diabetic retinopathy among individuals with type 2 diabetes: A systematic review and meta-analysis of observational studies.Diabetes Obes Metab2024https://conductscience.org/library/papers/38031234PubMed
1236203933The AMPK pathway in fatty liver disease.Front Physiol2022https://conductscience.org/library/papers/36203933PubMed
1324599780The impact of peri-operative anti-TNF treatment on anastomosis-related complications in Crohn's disease patients. A critical review.J Gastrointest Surg2014https://conductscience.org/library/papers/24599780PubMed
1439813121GLP-1 and the Neurobiology of Eating Control: Recent Advances.Endocrinology2025https://conductscience.org/library/papers/39813121PubMed
1537019448Dietary sugar consumption and health: umbrella review.BMJ2023https://conductscience.org/library/papers/37019448PubMed
1621148304Status of hemoglobin A1c measurement and goals for improvement: from chaos to order for improving diabetes care.Clin Chem2011https://conductscience.org/library/papers/21148304PubMed
1740105856Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity: A Systematic Review and Meta-Analysis.JAMA Psychiatry2025https://conductscience.org/library/papers/40105856PubMed
1825475437PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control.Diabetes2015https://conductscience.org/library/papers/25475437PubMed
1937993201Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction.J Am Coll Cardiol2023https://conductscience.org/library/papers/37993201PubMed
2039438043Glucagon-like peptide-1 receptor agonists before upper gastrointestinal endoscopy and risk of pulmonary aspiration or discontinuation of procedure: cohort study.BMJ2024https://conductscience.org/library/papers/39438043PubMed

See all 60 referencesDownload CSV of references

Cited by19

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 22 citations.

PMIDTitleJournalYearIn PapersSource
42909776Lessons from dog lifespan therapeutics for their human companions.Geroscience2026https://conductscience.org/library/papers/42909776PubMed
42889249Modern Obesity Treatment: Efficacy, Safety, and Future Directions of GLP-1 (Glucagon-Like Peptide-1) and GIP (Glucose-Dependent Insulinotropic Polypeptide) Receptor Agonists.Cureus2026https://conductscience.org/library/papers/42889249PubMed
42738922Lifestyle Medicine as Co-Therapy During Incretin-Based Anti-Obesity Pharmacotherapy: Integrating Physical Activity, Nutrition, and Behavioral Strategies for Long-Term Success.Nutrients2026https://conductscience.org/library/papers/42738922PubMed
42712076A Biweekly GLP-1R Agonist Designed With Drug-Free Intervals for Enhanced Efficacy, Receptor Homeostasis and Gastrointestinal Tolerability.Diabetes Obes Metab2026https://conductscience.org/library/papers/42712076PubMed
42683789Are Glucagon-Like Peptide-1 Receptor Agonists Suitable for Secondary Stroke Prevention?J Clin Neurol2026https://conductscience.org/library/papers/42683789PubMed
42668762Multisystem Benefits of GLP-1 Microdosing: A Narrative Review.Cureus2026https://conductscience.org/library/papers/42668762PubMed
42601733A cross-sectional survey on exploring adherence to diabetes treatment regimens: Insights from Hail region, Saudi Arabia.Medicine (Baltimore)2026https://conductscience.org/library/papers/42601733PubMed
42511630Psyllium and Glucomannan as Viscous Fiber Modulators of the Gut-Microbiome-Incretin Axis: Molecular Links to Metabolic Inflammation, Barrier Function, and GLP-1 Receptor Agonist Therapy.Int J Mol Sci2026https://conductscience.org/library/papers/42511630PubMed
42457963Food systems transformation would reshape global agriculture.Nature2026https://conductscience.org/library/papers/42457963PubMed
42451115Dual Activation of GLP-1 and AMPK Pathways by a Multi-Botanical Formulation Improves Obesity and Metabolic Dysfunction in Experimental Models.Nutrients2026https://conductscience.org/library/papers/42451115PubMed
42380553GLP-1-Based Therapies in Type 1 Diabetes: Emerging Evidence on Cardiovascular, Renal, and Safety Outcomes.Diabetes Obes Metab2026https://conductscience.org/library/papers/42380553PubMed
42280404Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support-A Narrative Review.Nutrients2026https://conductscience.org/library/papers/42280404PubMed
42249138Oral small molecule GLP-1 receptor agonist aleniglipron in people with overweight or obesity: a randomized, double-blind, placebo-controlled phase 2b trial.Nat Med2026https://conductscience.org/library/papers/42249138PubMed
42201157Beyond Glycemic Control: Ocular Effects of Glucagon-like Peptide-1 Receptor Agonists.Vision (Basel)2026https://conductscience.org/library/papers/42201157PubMed
42198298GLP-1 Receptor Agonists in Chronic Inflammatory Skin Diseases: Immunometabolic Mechanisms and Translational Perspectives.Pharmaceutics2026https://conductscience.org/library/papers/42198298PubMed
42131480GLP-1 receptor and Mitochondria-ER Contact Sites: an emerging mechanism of metabolic regulation.Front Physiol2026https://conductscience.org/library/papers/42131480PubMed
42074711Effects of GLP-1 Agonists on Patients with Hidradenitis Suppurativa: A Systematic Review.J Clin Med2026https://conductscience.org/library/papers/42074711PubMed
41786648Response to the Letter to the Editor on "Perioperative GLP-1 Receptor Agonist Use is Associated with Reduced Revisions and Complications Following ACDF: A Propensity-Matched Analysis".Global Spine J2026https://conductscience.org/library/papers/41786648PubMed
41683830Orforglipron: A Comprehensive Review of an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity and Type 2 Diabetes.Int J Mol Sci2026https://conductscience.org/library/papers/41683830PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
GLP1R2740PubTator's text mininghttps://conductscience.org/library/genes/2740

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41501059

GET https://conductscience.org/api/papers/v1/41501059/references?page=2